Navigation Links
WuXi PharmaTech Announces Third-Quarter 2013 Results
Date:11/12/2013

SHANGHAI, Nov. 12, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its unaudited financial results for the third quarter of 2013. 

Highlights

  • Net Revenues Increased 16.6% Year Over Year to $146.7 Million
  • Laboratory Services Net Revenues Grew 9.2% Year Over Year to $108.1 Million
  • China-Based Laboratory Services Net Revenues Increased 10.3% Year Over Year to $85.0 Million
  • U.S.-Based Laboratory Services Net Revenues Increased 5.4% Year Over Year to $23.1 Million
  • Manufacturing Services Net Revenues Increased 43.6% Year Over Year to $38.6 Million
  • GAAP Diluted Earnings Per ADS Grew 40.7% Year Over Year to $0.42
  • Non-GAAP Diluted Earnings Per ADS Increased 29.3% Year Over Year to $0.47
  • Full-Year 2013 Revenue Guidance Revised to $574-$578 Million, Full-Year 2013 Diluted EPS Guidance Increased to $1.51-$1.55 GAAP, $1.73-$1.77 Non-GAAP
  • Management Comment"WuXi achieved solid, broad-based revenue growth and stable margins in the third quarter," said Dr. Ge Li, Chairman and Chief Executive Officer.  "As a result, we again exceeded our financial guidance for the quarter. We expect this strong growth to continue throughout the remainder of 2013 and are increasing our full-year 2013 EPS guidance.

    "While achieving current growth, we are also making the investments necessary to sustain growth," Dr. Li continued. "In small-molecule manufacturing, we are planning to construct new research manufacturing and commercial manufacturing facilities that will substantially increase our capacity.  In August 2013, we successfully completed a general GMP and Pre-Approval Inspection from the U.S. Food and Drug Administration of our commercial manufacturing facility in Jinshan for the production of an advanced intermediate for a product with an NDA under FDA review, without the issuance of a Form 483.

    "Biologics is another area of current investment that will drive future revenue growth. We believe we have built the premier biologics drug discovery, development, and manufacturing business in China, and we expect it will be one of our fastest-growing businesses.

    "Genomics is another area where WuXi is demonstrating leadership in China.  We recently received CLIA certification from the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services for our genomics clinical laboratory in Shanghai, the only laboratory in China to receive such certification. Receipt of a CLIA certificate allows WuXi's genomics laboratory to undertake certain clinical trial gene sequencing projects.

    "These and other achievements demonstrate that we are succeeding in our mission of building an open-access technology and capability platform that enables anyone and any company to discover and develop therapeutic products to benefit patients," Dr. Li concluded.

    Third-Quarter 2013 GAAP ResultsThird-quarter 2013 net revenues increased 16.6% year over year to $146.7 million. Revenue growth in Laboratory Services of 9.2% was driven by our comprehensive and integrated discovery and development services, primarily in China. Revenue growth of 43.6% in Manufacturing Services was caused by strong growth in demand in both research and commercial manufacturing compared to the third quarter of 2012.

    Third-quarter 2013 GAAP gross profit increased 14.4% year over year to $52.7 million due to 16.6% revenue growth, offset by business mix, as the strongest revenue growth was achieved in Manufacturing Services, which has a lower gross margin than Laboratory Services.  Gross margin decreased year over year to 35.9% from 36.6%.  Gross margin in Laboratory Services decreased slightly year over year to 38.1% from 38.2% mainly due to the effects of increasing labor costs in China and appreciation of the RMB versus the U.S. dollar, partially offset by improved productivity and the ramp-up of biologics and preclinical services. Gross margin in Manufacturing Services decreased year over year to 30.0% from 30.7% due to project mix.

    Third-quarter 2013 GAAP operating income increased 26.8% year over year to $27.2 million due to the 14.4% increase in gross profit and lower general and administrative expenses in the quarter.  Operating margin increased to 18.5% from 17.0%, primarily due to lower general and administrative expenses.

    Third-quarter 2013 GAAP net income increased 42.7% year over year to $30.4 million due to the 26.8% year-over-year increase in operating income, higher other income primarily due to $3.1 million of realized gains and $2.6 million of mark-to-market gains on foreign-exchange forward contracts, higher interest income due to higher cash balances and higher interest rates, and a reduction in the effective tax rate due to the mix of taxable income, partially offset by $1.4 million of equity-method investment losses associated with our joint ventures with PRA and MedImmune.

    Third-quarter 2013 GAAP diluted earnings per ADS increased 40.7% to $0.42 due to the 42.7% increase in net income, partially offset by a higher number of outstanding ADSs as a result of the exercise of shares under employee stock option and restricted stock programs. Third-quarter 2013 GAAP comprehensive income increased 94.7% year over year to $39.3 million due to the 42.7% increase in GAAP net income, the increase in currency translation adjustments, and $6.6 million of unrealized gains from investments by our corporate venture fund in two U.S. biotech companies that had successful IPOs in the third quarter of 2013.

    Third-Quarter 2013 Non-GAAP ResultsNon-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact. 

    Third-quarter 2013 non-GAAP gross profit increased 13.1% year over year to $53.9 million, due to the 16.6% revenue growth, offset by business mix, as the strongest revenue growth was achieved in Manufacturing Services, which has a lower gross margin than Laboratory Services.  Non-GAAP gross margin decreased year over year to 36.7% from 37.8%, mainly due to revenue mix of faster-growing Manufacturing Services revenues with relatively low gross margin and the effects of increasing labor costs in China and appreciation of the RMB versus the U.S. dollar, partially offset by improved productivity and the ramp-up of biologics and preclinical services. 

    Third-quarter 2013 non-GAAP operating income increased 17.5% year over year to $31.3 million, primarily due to the 13.1% increase in non-GAAP gross profit.  Operating margin increased to 21.3% from 21.2% due to lower general and administrative expenses as a percentage of revenue, partially offset by lower gross margin.

    Third-quarter 2013 non-GAAP net income grew 31.2% year over year to $34.5 million due to the 17.5% increase in non-GAAP operating income, higher other income primarily due to $3.1 million of realized gains and $2.6 million of mark-to-market gains on foreign-exchange forward contracts, higher interest income due to higher cash balances and higher interest rates, and a reduction in the effective tax rate due to the mix of taxable income, partially offset by $1.4 million of equity-method investment losses associated with our joint ventures with PRA and MedImmune.

    Third-quarter 2013 non-GAAP diluted earnings per ADS grew 29.3% year over year to $0.47 due to the 31.2% increase in non-GAAP net income, partially offset by a higher number of outstanding ADSs as a result of the exercise of shares under the employee stock option and restricted stock programs.

    Full-Year 2013 Financial GuidanceWuXi PharmaTech updates its full-year 2013 financial guidance as follows:

  • Total net revenues of $574-578 million, or 15-16% year-over-year growth, compared to previous guidance of $572-578 million
  • GAAP and non-GAAP gross margin and operating margin comparable to those in 2012, the same as previous guidance
  • GAAP diluted earnings per ADS of $1.51-$1.55, compared to previous guidance of $1.38-$1.44
  • Non-GAAP diluted earnings per ADS of $1.73-$1.77, compared to previous guidance of $1.61-$1.67
  • Capital expenditures of about $60 million, the same as previous guidance
  • Fourth-Quarter 2013 Financial GuidanceWuXi PharmaTech provides the following fourth-quarter 2013 financial guidance:

  • Total net revenues of $153-157 million, or 22-25% year-over-year growth
  • GAAP diluted earnings per ADS of $0.38-$0.42
  • Non-GAAP diluted earnings per ADS of $0.44-$0.48
  • WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONSOLIDATED BALANCE SHEETS(in thousands of U.S. dollars, except ordinary share, ADS and par value data)September 30,
    2013December 31,
    2012Assets:Current assets:Cash and cash equivalents145,161

    54,133Restricted cash3,506

    423Short-term investments180,867

    175,245Accounts receivable, net119,384

    99,578Inventories41,074

    47,774Prepaid expenses and other current assets34,341

    18,807Total current assets524,333

    395,960Non-current assets:Goodwill31,085

    32,561Property, plant and equipment, net264,363

    264,381Long-term investments23,979

    14,015Intangible assets, net6,233

    7,268Land use rights5,591

    5,564Deferred tax assets2,545

    3,037Other non-current assets4,946

    19,749Total non-current assets338,742

    346,575Total assets863,075

    742,535Liabilities and equity:Current liabilities:Short-term and current portion of long-term debt49,406

    59,089Accounts payable30,763

    21,808Accrued expenses27,220

    27,411Deferred revenue22,527

    17,052Advanced subsidies11,435

    9,265Other taxes payable7

    1,581Other current liabilities14,128

    11,215Total current liabilities155,486

    147,421Non-current liabilities:Long-term debt, excluding current portion5,534

    5,697Advanced subsidies1,902

    2,663Long-term payables-

    732Other non-current liabilities7,149

    7,799Total non-current liabilities14,585

    16,891Total liabilities170,071

    164,312Equity:Ordinary shares ($0.02 par value, 5,002,550,000 authorized,  568,513,338 and 569,653,210 issued and outstanding as of December 31, 2012, and September 30, 2013, respectively) 11,393

    11,222Additional paid-in capital346,383

    331,714Retained earnings270,315

    188,604Accumulated other comprehensive income64,913

    46,683Total equity693,004

    578,223Total liabilities and equity863,075

    742,535 WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands of U.S. dollars, except ADS data and per ADS data)Three Months Ended
     September 30,Nine Months Ended
     September 30,20132012% Change20132012% ChangeNet revenues:Laboratory Services108,060

    98,925

    9.2%311,444

    279,119

    11.6%Manufacturing Services38,659

    26,919

    43.6%109,467

    95,134

    15.1%Total net revenues146,719

    125,844

    16.6%420,911

    374,253

    12.5%Cost of revenues:Laboratory Services(66,929)

    (61,097)

    9.5%(192,557)

    (174,840)

    10.1%Manufacturing Services(27,053)

    (18,657)

    45.0%(76,456)

    (64,938)

    17.7%Total cost of revenues(93,982)

    (79,754)

    17.8%(269,013)

    (239,778)

    12.2%Gross profit:Laboratory Services41,131

    37,828

    8.7%118,887

    104,279

    14.0%Manufacturing Services11,606

    8,262

    40.5%33,011

    30,196

    9.3%Total gross profit52,737

    46,090

    14.4%151,898

    134,475

    13.0%Operating expenses:Selling and marketing expenses(3,859)

    (3,594)

    7.4%(12,233)

    (10,601)

    15.4%General and administrative expenses(18,656)

    (19,302)

    (3.3%)(56,077)

    (52,374)

    7.1%Research and development expenses(3,031)

    (1,744)

    73.8%(7,707)

    (5,637)

    36.7%Total operating expenses(25,546)

    (24,640)

    3.7%(76,017)

    (68,612)

    10.8%Operating income27,191

    21,450

    26.8%75,881

    65,863

    15.2%Other income (expenses), net:Loss from equity-method investments(1,404)

    -

    NA(2,926)

    -

    NAOther income (expenses), net8,084

    3,103

    160.5%18,248

    5,263

    246.7%Interest income (expenses), net2,500

    1,399

    78.7%6,091

    4,523

    34.7%Total other income (expenses), net9,180

    4,502

    103.9%21,413

    9,786

    118.8%Income before income taxes36,371

    25,952

    40.1%97,294

    75,649

    28.6%Income tax expense(5,992)

    (4,669)

    28.3%(15,583)

    (12,885)

    20.9%Net income30,379

    21,283

    42.7%81,711

    62,764

    30.2%Other comprehensive income:Currency translation adjustments2,282

    (1,117)

    (304.3%)11,635

    (2,719)

    (527.9%)Unrealized gains on available-for-sale securities

    6,596

    -

    NA6,596

    -

    NAComprehensive income39,257

    20,166

    94.7%99,942

    60,045

    66.4%Basic net earnings per ADS0.43

    0.30

    41.5%1.16

    0.88

    31.4%Diluted net earnings per ADS0.42

    0.30

    40.7%1.13

    0.86

    31.5%Weighted average ADS outstanding - basic71,142,534

    70,507,167

    0.9%70,731,872

    71,375,430

    (0.9%)Weighted average ADS outstanding - diluted73,057,785

    72,001,577

    1.5%72,423,827

    73,168,508

    (1.0%) WUXI PHARMATECH (CAYMAN) INC.RECONCILIATION OF GAAP TO NON-GAAP(in thousands of U.S. dollars, except ADS data and per ADS data)Three Months Ended
     September 30,Nine Months Ended
     September 30,20132012% Change20132012% ChangeGAAP gross profit52,737

    46,090

    14.4%151,898

    134,475

    13.0%GAAP gross margin35.9%

    36.6%36.1%

    35.9%Adjustments:Share-based compensation1,067

    979

    9.0%3,247

    3,068

    5.8%Amortization of acquired intangible assets48

    525

    (90.9%)212

    1,575

    (86.5%)Non-GAAP gross profit53,852

    47,594

    13.1%155,357

    139,118

    11.7%Non-GAAP gross margin36.7%

    37.8%36.9%

    37.2%GAAP operating income27,191

    21,450

    26.8%75,881

    65,863

    15.2%GAAP operating margin18.5%

    17.0%18.0%

    17.6%Adjustments:Share-based compensation4,052

    4,661

    (13.1%)11,700

    10,906

    7.3%Amortization of acquired intangible assets48

    525

    (90.9%)212

    1,575

    (86.5%)Non-GAAP operating income31,291

    26,636

    17.5%87,793

    78,344

    12.1%Non-GAAP operating margin21.3%

    21.2%20.9%

    20.9%GAAP net income30,379

    21,283

    42.7%81,711

    62,764

    30.2%GAAP net margin20.7%

    16.9%19.4%

    16.8%Adjustments:Share-based compensation4,052

    4,661

    (13.1%)11,700

    10,906

    7.3%Amortization of acquired intangible assets48

    525

    (90.9%)212

    1,575

    (86.5%)Deferred tax impact related to acquired
    intangible assets(17)

    (195)

    (91.3%)(66)

    (584)

    (88.7%)Non-GAAP net income34,462

    26,274

    31.2%93,557

    74,661

    25.3%Non-GAAP net margin23.5%

    20.9%22.2%

    19.9%Income attributable to holders of ADS (Non-GAAP):Basic34,462

    26,274

    31.2%93,557

    74,661

    25.3%Diluted34,462

    26,274

    31.2%93,557

    74,661

    25.3%Basic earnings per ADS (Non-GAAP)0.48

    0.37

    30.0%1.32

    1.05

    26.4%Diluted earnings per ADS (Non-GAAP)0.47

    0.36

    29.3%1.29

    1.02

    26.6%Weighted average ADS outstanding
    8211; basic (Non-GAAP)71,142,534

    70,507,167

    0.9%70,731,872

    71,375,430

    (0.9%)Weighted average ADS outstanding
      – diluted (Non-GAAP)73,057,785

    72,001,577

    1.5%72,423,827

    73,168,508

    (1.0%) WUXI PHARMATECH (CAYMAN) INC.REVENUE BREAKDOWN(in thousands of U.S. dollars)Three Months Ended
     September 30,Nine Months Ended
     September 30,20132012% Change20132012% ChangeNet revenues:China-based Laboratory Services85,000

    77,055

    10.3%242,844

    211,801

    14.7%China-based Manufacturing Services38,659

    26,919

    43.6%109,467

    95,134

    15.1%Subtotal123,659

    103,974

    18.9%352,311

    306,935

    14.8%U.S.-based Laboratory Services23,060

    21,870

    5.4%68,600

    67,318

    1.9%Total net revenues146,719

    125,844

    16.6%420,911

    374,253

    12.5%Conference CallWuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 9:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, November 13, 2013, to discuss its third-quarter 2013 financial results and future prospects.  The conference call may be accessed by calling:

    China

    4001 200 539Hong Kong

    800 905 927Singapore

    800 616 3222United Kingdom

    0800 015 9725United States

    1855 298 3404United States - New York (toll)

    +1 631 5142 526Other countries (toll)

    +65 6823 2299Conference ID

    5522969A telephone replay will be available two hours after the call's completion at:

    China

    4001 842 240Hong Kong

    800 966 697Singapore

    800 616 2127United Kingdom

    0800 169 7301United States

    1866 846 0868Conference ID

    5522969A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com.

    About WuXi PharmaTechWuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts, but instead are predictions about future events. Examples of forward-looking statements in this press release include statements about our fourth-quarter and full-year 2013 guidance and our goal of building an open-access technology platform. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to control our costs and sustain revenue growth, to realize the anticipated benefits of our investments, to protect our clients' intellectual property, and to compete effectively. Additional information about these and other relevant risks can be found in our Annual Report on Form 20-F for the year ended December 31, 2012. The forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by law.

    Use of Non-GAAP and Pro-Forma Financial Measures  We have provided the third-quarter and nine-months 2012 and 2013 gross profit, gross margin, operating income, operating margin, net income, net margin, and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses and the amortization and deferred tax impact of acquired intangible assets. We believe both management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue to provide net income and earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and you should refer to the reconciliation of GAAP measures to non-GAAP measures for the indicated periods in this press release.

    Statement Regarding Unaudited Financial InformationThe financial information in this press release is unaudited and subject to adjustments. Adjustments to the financial statements may be identified when our annual financial statements are prepared and audit work is performed for the year-end audit, which could result in significant differences from this unaudited financial information.

    For more information, please contact:Ronald Aldridge (for investors)
    Director of Investor Relations 
    Tel:
    +1-201-585-2048
    Email: ron_aldridge@wuxiapptec.com Aaron Shi (for the media)
    Associate Director of Corporate Communications 
    Tel:
    +86-21-5046-4362
    Email: aaron_shi@wuxiapptec.com


    '/>"/>
    SOURCE WuXi PharmaTech
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
    2. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
    3. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
    4. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
    5. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
    6. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
    7. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
    8. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
    9. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
    10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
    11. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
    (Date:2/5/2016)... Feb. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... previously announced underwritten secondary offering of 11,027,558 shares of ... of affiliates of Blackstone and Goldman Sachs.  The shares ... price of $96.45 per share. The selling stockholders will ... Zimmer Biomet nor any of its directors, officers or ...
    (Date:2/5/2016)... France , Germany ... and Israel ). It includes a 10-year epidemiology forecast ... segmented by age and sex in these markets. GD epidemiology report is ... in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends ... Germany , Italy , Spain ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV ... the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream ... Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors ...
    (Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
    (Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: ... wait longer to access the treadmills. It’s a predictable trend. After the excesses of ... and get in shape by joining gyms, starting new walking or running routines, or ...
    (Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
    Breaking Medicine News(10 mins):